-+ 0.00%
-+ 0.00%
-+ 0.00%

Deqi Pharmaceutical-B (06996): ATG-201 Phase I ATTRACT study for treatment of B-cell-mediated autoimmune diseases was approved by HREC in Australia

Zhitongcaijing·08/25/2026 00:57:04
Listen to the news

Zhitong Financial App News, Deqi Pharmaceutical-B (06996) issued an announcement. The board of directors of the company is pleased to announce that the phase I ATTRACT study of ATG-201 (a CD19/CD3 bispecific T-cell bridging antibody for treatment of B-cell-related autoimmune diseases) has been approved by the Australian Human Research Ethics Committee (HREC) and has completed the process of submitting a clinical trial notice (CTN) to the Therapeutic Goods Administration (TGA).